Santhera Pharmaceuticals (Switzerland) Ltd.

Hohenrainstrasse
4133 Pratteln
Display on the map

Employee CH: 100
Sector: Chemicals/Pharmaceuticals
Revenue last year: No information available
Stock exchange: No information available
Further information

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases.
In September 2015 our product, Raxone®, received European Marketing Authorization in the treatment of patients with LHON (Leber's Hereditary Optic Neuropathy). Raxone® is not only the first and only medicine approved for this condition, but it is also the first medicine approved for any mitochondrial disorder.
Raxone® is also investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and Primary Progressive Multiple Sclerosis (PPMS). In addition, Santhera’s pipeline includes omigapil, an investigational drug with anti-apoptotic properties, a compound in development to address unmet medical needs for patients with Congenital Muscular Dystrophy (CMD).
In February 2018, Santhera obtained the worldwide, exclusive rights to develop and commercialize POL6014, an innovative macrocycle elastase inhibitor with the potential to treat Cystic Fibrosis and other Pulmonary Diseases.

For more information, please visit the company's website www.santhera.com

Full description

More about this Company on

No reviews yet

Help other job seekers and be the first one to write a review.

Current Vacancies at Santhera Pharmaceuticals (Switzerland) Ltd.